Kornimate/medical-research-clean huggingface dataset:
role of metabolites in nicotine dependence (4) - 13

Conditions: Tobacco Use Disorder

Summary: the purpose of this study is to determine the effects of cotinine with or without a transdermal nicotine replacement on tobacco withdrawal symptoms.

previous studies have shown that cotinine, a metabolite of nicotine, antagonizes some of the effects of nicotine. one study showed that nicotine eliminates some of the beneficial effects of the nicotine patch in reducing withdrawal symptoms. the purpose of this study was to replicate and extend these findings and examine the effects of various doses of cotinine base compared placebo on withdrawal symptom as well as drug preference among abstinent smokers while using the nicotine patch. we hypothesized that cotinine will reduce the beneficial effects of the nicotine patch in reducing withdrawal symptoms and that placebo will be preferred over cotinine during the forced drug choice period.

Eligibility criteria:
inclusion criteria: male/female subjects, aged 21-45 years inclusive, with a smoking history of at least 20 cigarettes daily (greater than or equal to 50) for at lease 1 year. subject is in good health as verified by medical history, screening examination, and screening laboratory tests as outlined above. subject has provided written informed consent to participate in the study and is motivated to stop smoking. subject has experienced at least 4 withdrawal symptoms upon abstinence. exclusion criteria: history of myocardial infarction, angina pectoris, sustained or episodic cardiac arrhythmias, symptomatic peripheral vascular disease, current peptic ulcer disease or any other medical condition which the physician investigator deems inappropriate for subject participation. insulin-dependent diabetes. pregnant or lactating, or not using adequate birth control methods. requirement of any form of regular psychotropic medication (antidepressants, antipsychotics, or anxiolytics) and recent psychiatric history (less than 1yr). chronic use of systemic steroids or antihistamines. abuse of alcohol or any other recreation aor prescription drug (more tha 3 drinks per day or 21 drinks per week). use of any other nicotine products, including smokeless tobacco, cigars and nicotine replacement products. inability to fulfill all scheduled visits and examination procedures throughout the study period. history of schizophrenia or manic depressive disorder. recent history of other psychiatric illness;less than 1 year since last episode of major depressive episode.

Keywords: nicotine dependence
chart review of patients undergoing ketamine infusions

Conditions: Major Depressive Disorder; Bipolar Disorder; Obsessive-Compulsive Disorder; Post Traumatic Stress Disorder

Summary: the canadian rapid treatment center of excellence (crtce) is a healthcare facility principally focused on providing best practices of intravenous ketamine treatment to adult patients suffering from mental health conditions. the center focuses specifically on treating individuals suffering from major depression disorder, bipolar disorder, post-traumatic stress disorder and obsessive compulsive disorder as their primary diagnosis. herein, this retrospective analysis aims to look at past data in order to further develop our understanding of ketamine in the use of psychiatry.


Eligibility criteria:
inclusion criteria: 1. over the age of 18 years old. patients over the age of 65 must receive additional approval to ensure safety. 2. diagnosed with either mdd, bd, ptsd or ocd by a healthcare provider. 3. experiencing an mde as defined and operationalized in the dsm 5.0. 4. individuals who may have comorbid psychiatric conditions, but the comorbid psychiatric condition can be neither the primary condition or the primary clinical concern. 5. individuals reporting suicidal ideation will be included, as suicidal ideation is a symptom of mde. 6. individuals must have received at least 2 guideline concordant treatment trials with pharmacotherapeutic treatment options as suggested in the canmat mdd guidelines 2016, florida medicaid guidelines 2017, or the canmat isbd guidelines for bd 2013. 7. individuals who have received ect or other neuromodulatory treatments will be eligible for ketamine infusion. exclusion criteria: 1. individuals who meet dsm 5 criteria for a substance use and/or alcohol use disorder in the past 3 months. 2. individuals who are experiencing psychotic symptoms as part of an mde (mood congruent/mood incongruent). 3. individuals who are unable to consent to the treatment. 4. individuals who are unable to adhere to the protocol in its totality (i.e., remain in the clinic post infusion for up to 2-3 hours for observation). 5. individuals who are unable to identify a person to assure their safe transport home following ketamine infusion. 6. individuals with symptomatic traumatic brain injury. 7. uncontrolled medical disorders (i.e., uncontrolled and/or insufficiently treated hypertension, allergies to ketamine and/or previous intolerability of ketamine). 8. pregnancy. 9. medical contraindications to ketamine. 10. patients that are over 275 lbs
comparison of efficacy of probiotic toothpaste and chlorhexidine mouthwash to reduce s.mutans

Conditions: White Spot Lesion of Tooth; Long Term Adverse Effects; Caries, Dental; Orthodontic Appliance Complication

Summary: orthodontic appliance causes increase in plaque accumulation, especially around brackets, wires and attachments. advances in orthodontics in recent time have led to improved quality of appliance and treatment procedures ultimately resulting in improvised standard of patient care. these bacteria metabolize different kind of carbohydrates accumulated around orthodontic appliances and create acidic environment in the oral cavity leading to enamel demineralization around the brackets and white spot lesions. this study was carried out to evaluate and compare the efficacy of probiotic toothpaste and chlorhexidine mouthwash in patients undergoing orthodontic treatment with individuals who are not using them.

introduction - when the basic oral hygiene is poor, orthodontic appliances create areas where plaque gets accumulated, especially around brackets, bands, wires, and other attachments; this facilitates the development of white spot lesions. probiotics act by competitively inhibiting the pathogenic bacteria because they have greater adhesion to the tissues while chlorhexidine is often used as an active ingredient in mouthwash designed to reduce dental plaque around orthodontic appliances. aim \& objective - the objectives of the study is to evaluate and compare the effects of the topical application of probiotic toothpaste and chlorhexidine mouthwash on the streptococcus mutans levels in the plaque of orthodontic patients hence improving the oral micro-flora of oral cavity by competitive inhibition of streptococcus mutans in plaque present around brackets. material \& method - the study consists of thirty randomly selected orthodontic patients undergoing fixed appliance treatment. the patients were divided into three groups - control group (group 1), probiotic toothpaste group (group 2) \& chlorhexidine mouthwash group (group 3). samples were collected at two times interval: before the study began (phase 1) and after thirty days (phase 2).

Eligibility criteria:
inclusion criteria: * orthodontic treatment with the straight wire appliance (mbt, 0.022-in slot; 3m unitek, monro- via, calif), permanent dentition (excluding third molars) * good general health (no significant medical history or drug use during the last month) * no anti-inflammatory or antibiotic medications taken in the month before the study * no chewing gum or, mouthwash used in the last week and during the study * habit of brushing twice daily with fluoride toothpaste exclusion criteria: -patient with poor periodontal condition patient with known medical condition e.g. subacute bacterial, endocarditis , diabetes, valvular disease ,anaemia etc

Keywords: white spot lesion probiotics chlorhexidine streptococcus mutans fixed orthodontic treatment
monthly versus two doses of ante-natal intermittent preventive treatment with sulphadoxine-pyrimethamine

Conditions: Malaria

Summary: randomized controlled prospective comparative study

this study is intended to be a randomized controlled comparative study conducted to compare the effect of monthly versus two doses of ante-natal intermittent preventive treatment with sulphadoxine-pyrimethamine

Eligibility criteria:
inclusion criteria: * pregnant women * gestational age between 16 and 28weeks. * no history of use of sulphadoxine-pyrimethamine prior to recruitment * not on any medication for prophylaxis exclusion criteria: * anaemia * hiv positive women * pre-existing medical conditions e.g diabetes mellitus, haemoglobinopathy, hypertension, kidney disease, heart disease, any endocrine disorder like hypo/hyperthyroidism, cushing' disease, connective tissue disorders like systemic lupus erythematosus, antiphospholipid syndrome or any otherautoimmune disease with poor feto-maternal outcomes in pregnancy. * history of glucose -6-phosphate dehydrogenase (g6pd) deficiency in patient * allergy to sulphonamides or pyrimethamine. * non consenting patients * multiple gestations
reducing food insecurity during covid-19

Conditions: Food Insecurity

Summary: this study aims to compare the effectiveness of two interventions to address food insecurity among low-income families with young children during the covid pandemic. the investigators will conduct a parallel group, randomized controlled trial of 250 families. the first randomly assigned comparator is fresh connect, a produce prescription program that provides a stipend for participants to purchase fresh food items at mobile markets and independent farmers markets across boston. the second comparator is grocery store gift cards, redeemable at conventional grocery stores. in each comparator, participants will be given the equivalent of $150 on a monthly basis for six consecutive months. all participants will be followed for 12 months to assess outcomes that involve food insecurity (primary), fruit and vegetable consumption, healthcare utilization, social service utilization, and physical/emotional health.


Eligibility criteria:
inclusion criteria: * parent of a child 0-18 months of age * child receives care at boston medical center exclusion criteria: * planning to move residence outside of boston within 12 months

Keywords: produce prescription program mobile markets grocery store gift cards fruit and vegetable consumption low-income families social determinants of health
study of tumor infiltrating lymphocytes following ccrt in the treatment of patients with cervical carcinoma

Conditions: Cervical Carcinoma

Summary: a phase i trial to evaluate the feasibility, toxicity and effectiveness of cisplatin concurrent chemoradiotherapy plus til in treating patients with figo stage iiia to iva cervical carcinoma.

concurrent chemoradiotherapy (ccrt) was the standard treatment for locoregionally advanced cervical cancer, while the incidence of treatment failure is still high. adjuvant chemotherapy or inducing chemotherapy addition to ccrt did not significantly improve patient survival compared to ccrt alone. hence, there is a need for novel therapies to improve survival for these patients. accumulating evidence shows that tumor-infiltrating lymphocytes (tils) selected for tumor recognition and greatly expanded in vitro are effective for treating cervical cancer patients. this is a phase i trial to evaluate the feasibility, toxicity and effectiveness of cisplatin concurrent chemoradiotherapy plus til in treating patients with figo stage iiia to iva cervical carcinoma.

Eligibility criteria:
inclusion criteria: * patients with histologically proven squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervical uteri * patients with stage iiia-iva cervical cancer according to the international federation of gynecology and obstetrics (figo) * patients who were ≥ 18 and ≤ 70 years old * patients with an ecog performance status of 0, 1, or 2 * adequate hematological, renal, and hepatic functions defined as: granulocytes ≥ 1.5 x 109/l, platelets ≥ 100 x 109/l, total bilirubin, alt and ast ≤ 1.5 x upper normal limit, creatinine ≤ upper normal limit * patients provided written, voluntary informed consent * patients who were accessible to follow up and management in the treatment center exclusion criteria: * patients with past or current history of malignancy other than the entry diagnosis except for a "cured" malignancy more than five years prior to enrollment * patients who received previous chemotherapy or radiotherapy * patients with active angina or documented myocardial infarction within the 6 months preceding registration and patients with a history of significant ventricular arrhythmia requiring medication or congestive heart failure, as well as a history of 2nd or 3rd degree heart blocks * patients with an active infection or other serious underlying medical conditions that would impair the ability of the patient to receive the planned treatment, including prior allergic reactions to drugs containing platinum * patients with dementia or altered mental status that would prohibit the understanding and providing of informed consent * patients with inadequate caloric and/or fluid intake

Keywords: tumor infiltrating lymphocytes concurrent chemotherapy
pda for kidneys study

Conditions: Patent Ductus Arteriosus; Congenital Heart Disease

Summary: the goal of this observational study is to gather more information on kidney oxygen levels in babies with a patent ductus arteriosus (pda), and evaluate the relationships between kidney oxygen levels, pda status and kidney injury. researchers will do this by looking at ultrasound images of the heart, analyzing substances in the urine, and evaluating oxygen levels in the kidneys.


Eligibility criteria:
inclusion criteria: * delivered at \<32 weeks' gestation * ≤72 hours of age * inpatient at meriter hospital, inc. nicu * at least one parent/guardian is able to provide parental permission in english or spanish exclusion criteria: * major congenital anomalies of kidney * attending physician's discretion to not place nirs sensors due to clinical concerns * in the pi or co-i's medical opinion, there is a significant likelihood that the neonate would not survive the first 3 days of life * birth parent aged \<18

Keywords: neonate
study of rad001 in patients with relapsed/refractory hodgkin lymphoma that has progressed after high-dose chemotherapy and autologous stem cell transplant and/or after gemcitabine- or vinorelbine- or vinblastine-based treatment.

Conditions: Hodgkin Lymphoma

Summary: this study will assess rad001 in patients with refractory or relapsed hodgkin lymphoma that has progressed after high-dose chemotherapy and autologous stem cell transplant and/or after gemcitabine- or vinorelbine- or vinblastine-based treatment.


Eligibility criteria:
inclusion criteria: * patients with a history of classical hodgkin's lymphoma that has progressed after high-dose chemotherapy and autologous stem cell transplant and/or after gemcitabine- or vinorelbine- or vinblastine-based treatment * patients with at least one site of measurable disease measuring ≥ 2.0cm confirmed by pet and ct scan (or mri) * patients with adequate bone marrow, liver and renal function (confirmed by laboratory values) * patients with fasting serum cholesterol ≤300 mg/dl or ≤7.75 mmol/l and fasting triglycerides ≤ 2.5 x uln exclusion criteria: * previous treatment with mtor inhibitors * prior allogeneic stem cell transplant * chemotherapy, monoclonal antibody therapy, major surgery or treatment with other investigational drugs within 4 weeks of starting study treatment * another malignancy within 3 years of study entry (except adequately treated non-melanoma skin cancer and carcinoma in situ of the cervix) * severe and/or uncontrolled medical conditions that could affect participation in this study * female patients who are pregnant or breastfeeding; patients who are not willing to use adequate birth control during the study and for 8 weeks after the last study treatment other protocol-defined inclusion/exclusion criteria may apply

Keywords: hodgkin's lymphoma hodgkin lymphoma hodgkin's disease hodgkin disease lymphoma lymphoproliferative disorders neoplasms by histological type lymphatic diseases hemic and lymphatic diseases recurrent lymphoma refractory lymphoma relapsed lymphoma classical hodgkin lymphoma classical hodgkin's disease nodular sclerosing hodgkin lymphoma mixed-cellularity hodgkin lymphoma lymphocyte-rich hodgkin lymphoma lymphocyte depleted hodgkin lymphoma
prophylactic injection therapy reduces recurrent bleeding in forrest type iib duodenal ulcers

Conditions: Duodenal Ulcer Bleeding

Summary: the purpose of this study is to determine whether prophylactic injection therapy reduces recurrent bleeding rate for duodenal ulcers which has the endoscopic stigmata of recent bleeding.

the benefit of endoscopic therapy in ulcers with adherent clots on their surface is still uncertain. a prophylactic injection therapy may reduce the recurrent bleeding rate at this group of patients having this endoscopic stigma of recent bleeding. this type of ulcers are named as type iib duodenal ulcers according to forrest's classification, they cary the risk of bleeding recurrence up to 36 percent and as it is reported previously there may be a 12 fold increasement in morbidity and mortality in such cases. a prophylactic endoscopic injection therapy may reduce the risk of recurrent bleeding in this group of the patients.

Eligibility criteria:
inclusion criteria: * endoscopic diagnose of forrest type 2b duodenal ulcer. exclusion criteria: * patients at whom the onset of upper gastrointestinal system bleeding symptoms exceeded 24 hours at index endoscopy. * patients having hemodynamic instability: systolic blood pressure below 90 mm/hg, heart rate above 110/min * demonstration of hemoglobin fall more than 2 g/dl in two hours. * patients with coexisting ulcers elsewhere than in duodenum. * patients under anticoagulant therapy other than aspirin.

Keywords: duodenal ulcer upper gastrointestinal system bleeding injection therapy
eurad mri classification of us indeterminate adnexa lesions

Conditions: Ovarian Tumor

Summary: this research is targeting patients with sonographically indeterminate adnexal mass that are being referred for clinical mr imaging. investigators from the uw will be contributing coded mr images and associated health information (us results, laboratory/pathology results) to the eurad trial. in addition, outcomes data on each patient will be sent at month 24 of the research.

an adnexal mass is the most common indication for gynaecological surgery. pre operative characterization is crucial and a scoring system would be useful to standardize the imaging report and thus, improve patients management. recently, the coordinating center developed the first mr scoring system named andexmr scoring system in a retrospective study which is accurate and reproducible. the objectives of this trial are to perform an external prospective validation of this scoring system to evaluate its potential impact on therapeutic strategy and to test its reproducibility. this is a prospective large multicenter study. all patients with a sonographically indeterminate adnexal mass referred for mr imaging will be included from each participating center. one senior and one junior radiologists independently analyze the different mr criteria to characterize adnexal masses. the reader will then classify the mass using adnexmr scoring system.

Eligibility criteria:
inclusion criteria: * patients 18 years of age or older * with indeterminate ultrasonographic adnexal mass exclusion criteria: * patients under 18 years of age
evolution of covid-19 in anticoagulated or antiaggregated patients (corona study)

Conditions: Covid19

Summary: corona is a retrospective, observational, one center study to investigate the clinical evolution (in terms of survival and thromboembolic complications) of patients on chronic treatment with anticoagulants or antiplatelet agents who are admitted to the hospital for covid-19 compared with patients who do not receive anticoagulants or antiplatelet agents.


Eligibility criteria:
inclusion criteria: * patient admitted for covid-19 at the hospital de la santa creu i sant pau, * positive covid-19 polymerase chain reaction test * length of stay more than 24 hours exclusion criteria: * no objective diagnose for covid-19 * outpatient * lenght of stay less than 24hours

Keywords: covid19 oral anticoagulant vka doac antiplatelet therapy heparin low molecular-weight heparin
ai-based measurements of tumour burden in psma pet-ct

Conditions: Prostate Cancer

Summary: the primary aim of the present study is to evaluate how automatically calculated (by an ai-based method) tumour burden, measured as tumour volume (tv) and as tumour uptake (tu: tv x suvmean) in the prostate/prostate bed, pelvic lymph nodes, distant lymph nodes, bone and as the total tumour burden predicts overall survival (os) in patients with prostate cancer (newly diagnosed and patients with biochemical recurrence).

in sweden, prostate cancer is diagnosed in 10,000 men annually and the mortality rate of 2,400 is among the highest worldwide. some prostate cancers are at high risk of metastatic progression to lethal disease and require correct staging or detection of recurrence and multidisciplinary treatments. the investigators have developed an ai-based method to detect and quantify tumours and metastases in 18f-psma-1007 pet-ct scans in patients with prostate cancer. the method can find tumours in the prostate and metastases in pelvic lymph nodes, distant lymph nodes and in bone, both in patients referred to the pet-ct scan for primary staging of high-risk prostate cancer for secondary staging due to recurrence. patients referred to clinically indicated psma pet-ct due to either initial staging of primary high-risk prostate cancer or due to biochemical recurrence will be eligible for inclusion. the ai-based method will automatically calculate tv, tu and number of suspected lesions and this information will be stored in a database. the values will after a 5 year follow-up period be analysed with regard to overall survival (os) and progression-free survival (pfs). the primary aim of the present study is to evaluate how tumour burden, measured as tv and as tumour uptake (tu: tv x suvmean) in the prostate/prostate bed, pelvic lymph nodes, distant lymph nodes, bone and as the total tumour burden predicts overall survival (os) in patients with prostate cancer (newly diagnosed and patients with biochemical recurrence). a secondary aim is to evaluate how the ai-derived measurements predict time to biochemical recurrence in a sub-cohort of patients with newly diagnosed high-risk prostate cancer. tertiary aims are to evaluate the difference in tv and tu measured with two different segmentation methods (a threshold of 50% of suvmax in each lesion and a threshold of suv 4) in relation to os and biochemical pfs. the impact of the number of automatically calculated suspected lesions will also be investigated regarding os and biochemical pfs as well as to the difference in tumour burden measured with ai and manually.

Eligibility criteria:
inclusion criteria: * patients referred to a clinically indicated 18f-psma-1007 pet-ct scan at skåne university hospital, lund or malmö, sweden exclusion criteria: * patients under 20 years old

Keywords: artificial intelligence 18f-psma-1007